Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service

This retrospective study included 353 patients with AML treated with CPX-351 in England. At median 10.9 months from diagnosis, median overall survival was 12.9 months and Day 30 all-cause mortality was 6% (17.3 vs. 11.7 months and 4% vs. 6%, respectively, for

Source: Clinical Lymphoma, Myeloma and Leukemia - July 10, 2023 Category: Hematology Authors: Alex Legg, Alexandrina Lambova, Anne Broe, Julia Levy, Greg Medalla Tags: Original Study Source Type: research